



Interferon gamma, lipopolysaccharide, and modified-live viral vaccines stimulation alter the mRNA expression of tumor necrosis factor α , inducible nitric oxide synthase, and interferon β in bovine alveolar macrophages

メタデータ	言語: eng 出版者: 公開日: 2022-01-26 キーワード (Ja): キーワード (En): 作成者: Ishikawa, Shingo, Miyazawa, Masataka, Tanaka, Chiho, Uesawa, Ryoma, Nishizawa, Juri, Uemura, Ryoko, Kobayashi, Ikuo, Hobo, Seiji メールアドレス: 所属:
URL	http://hdl.handle.net/10466/00017577

Veterinary Immunology and Immunopathology

Interferon gamma, lipopolysaccharide, and modified-live viral vaccines stimulation alter the mRNA expression of tumor necrosis factor α , inducible nitric oxide synthase, and interferon β in bovine alveolar macrophages

--Manuscript Draft--

Manuscript Number:	VETIMM-D-21-00171R1
Article Type:	Short Communication
Keywords:	alveolar macrophage; modified-live viral vaccine; Innate immunity; cytokines; PAMPs
Corresponding Author:	Seiji Hobo, Ph.D. Kagoshima Daigaku Kagoshima, Kagoshima JAPAN
First Author:	Shingo Ishikawa
Order of Authors:	Shingo Ishikawa Masataka Miyazawa Chiho Tanaka Ryoma Uesawa Juri Nishizawa Ryoko Uemura Ikuo Kobayashi Seiji Hobo, Ph.D.
Abstract:	<p>To understand the pathogenesis of bovine respiratory disease (BRD), it is necessary to elucidate the mechanisms of alveolar macrophage regulation by cytokines and pathogen-associated molecular patterns (PAMPs). Moreover, "trained immunity," an innate immune regulatory mechanism in response to vaccines containing PAMPs, has recently attracted attention. It may be applied to BRD control, but there is limited knowledge in bovine. To investigate this, we stimulated alveolar macrophages in vitro with lipopolysaccharide (LPS), polyinosinic-polycytidylic acid sodium salt (Poly I:C), interferon gamma (IFN-γ), and modified-live viral (MLV) vaccines, respectively, and analyzed changes in interferon beta (IFN-β), tumor necrosis factor alpha (TNF-α), and inducible nitric oxide synthase (iNOS) mRNA expression levels. mRNA expression levels of TNF-α, iNOS, and IFN-β were significantly increased in bovine alveolar macrophages stimulated by IFN-γ and MLV vaccine; LPS, IFN-γ, and MLV vaccine; and MLV vaccine only, respectively. Additionally, all MLV vaccine-stimulated mRNA expression increases were observed in a concentration-dependent manner. These results revealed in part, the mechanism of bovine alveolar macrophage regulation by cytokines and PAMPs. Understanding the regulatory mechanisms of alveolar macrophages will contribute to understanding the pathogenesis of BRD and preventive and therapeutic BRD management based on trained immunity.</p>
Response to Reviewers:	

Highlights

- IFN- γ and PAMPs alter bovine alveolar macrophage mRNA expression
- MLV vaccine alter bovine alveolar macrophage mRNA expression
- The effects of PAMPs on bovine alveolar macrophages vary with the type of PAMP
- PAMPs in modified-live viral vaccines directly stimulate alveolar macrophages

Fig. 1






Table 1. Sequences of primers used for PCR

Primer	Kind	Sequence (5'—3')	Accession Number
TNF- α	Sense	TTGCTTGTGCCTCAGCCTCT	NM_173966.3
	Antisense	GGGACTGCTCTCCCTCTGG	
iNOS	Sense	AAAACCCACGTCTGGCAGGA	NM_001076799.1
	Antisense	GGCGAAGAACACGGCTTTGA	
IFN- β	Sense	GAGGAGATGAAGCAAGAACAGCA	NM_174350.1
	Antisense	TCTGGTGAGAATGCCGAAGA	
β -actin	Sense	CCCAGATCATGTTTCGAGACC	NM_173979.3
	Antisense	GAGGCATACAGGGACAGCAC	

Conflict of Interest

The authors declare the following financial interests/personal relationships that may be considered potential conflict of interests: SI received research funding from Zoetis Japan Inc. None of the other authors have conflicting financial interests.

1 Short communication

2 Interferon gamma, lipopolysaccharide, and modified-live viral vaccines stimulation alter
3 the mRNA expression of tumor necrosis factor α , inducible nitric oxide synthase, and
4 interferon β in bovine alveolar macrophages

5

6 Shingo Ishikawa^{a,b}, Masataka Miyazawa^b, Chiho Tanaka^b, Ryoma Uesawa^b, Juri
7 Nishizawa^b, Ryoko Uemura^c, Ikuo Kobayashi^c, and Seiji Hobo^{b,*}

8 ^aDivision of Veterinary Science, Graduate School of Life and Environmental Biosciences,
9 Osaka Prefecture University, Izumi-Sano, Osaka, 598-8531, Japan

10 ^bJoint Faculty of Veterinary Medicine, Kagoshima University, 1-21-24 Korimoto,
11 Kagoshima, 890-0065, Japan.

12 ^cCenter for Animal Disease Control, University of Miyazaki, 1-1 Gakuenkibanadai-nishi,
13 Miyazaki 889-2192, Japan

14

15 *Corresponding author: Seiji Hobo

16 Joint Faculty of Veterinary Medicine, Kagoshima University
17 1-21-24 Korimoto, Kagoshima 890-0065, Japan

18 E-mail address: k2088185@kadai.jp, Fax: +81-992853538

19

20 Abstract

21 To understand the pathogenesis of bovine respiratory disease (BRD), it is
22 necessary to elucidate the mechanisms of alveolar macrophage regulation by cytokines
23 and pathogen-associated molecular patterns (PAMPs). Moreover, "non-specific effects
24 (NSEs)" an innate immune regulatory mechanism in response to vaccines containing
25 PAMPs, has recently attracted attention. It may be applied to BRD control, but there is
26 limited knowledge in bovine. To investigate this, we stimulated alveolar macrophages *in*
27 *vitro* with lipopolysaccharide (LPS), polyinosinic-polycytidylic acid sodium salt (Poly
28 I:C), interferon gamma (IFN- γ), and modified-live viral (MLV) vaccines, respectively,
29 and analyzed changes in tumor necrosis factor alpha (TNF- α), inducible nitric oxide
30 synthase (iNOS), and interferon beta (IFN- β) mRNA expression levels. mRNA
31 expression levels of TNF- α , iNOS, and IFN- β were significantly increased in bovine
32 alveolar macrophages stimulated by IFN- γ and MLV vaccine; LPS, IFN- γ , and MLV
33 vaccine; and MLV vaccine only, respectively. Additionally, all MLV vaccine-stimulated
34 mRNA expression increases were observed in a concentration-dependent manner. These
35 results revealed in part, the mechanism of bovine alveolar macrophage regulation by
36 cytokines and PAMPs. Understanding the regulatory mechanisms of alveolar
37 macrophages will contribute to understanding the pathogenesis of BRD and preventive

38 and therapeutic BRD management based on **NSEs**.

39

40 Keywords: bovine; alveolar macrophage; modified-live viral vaccine; innate immunity;

41 cytokines; PAMPs

42

43 Abbreviations

44 BRDC: Bovine respiratory disease complex; MLV: Modified-live viral; PAMPs:

45 Pathogen-related molecular patterns; PRRs: Pattern recognition receptors; LPS:

46 Lipopolysaccharide; Poly I:C: Polyinosinic-polycytidylic acid sodium salt; IFN:

47 Interferon; IL: Interleukin; TNF: Tumor necrosis factor; iNOS: Inducible nitric oxide

48 synthase; BALF: bronchoalveolar lavage fluid; RPMI: Roswell Park Memorial Institute;

49 FBS: Fetal bovine serum

50

51 1. Introduction

52 Bovine respiratory disease (BRD), a complex infection caused by the
53 intertwining of various pathogens and stress (Griffin et al., 2010), is the most common
54 disease in cattle, and it causes great economic losses (Edwards, 2010). Some of the
55 causative pathogens of BRD, such as *Mycoplasma bovis*, do not have a vaccine and are
56 difficult to treat with antibiotics; thus, complicating respiratory disease countermeasures
57 (Maunsell et al., 2011). The internal respiratory organ is in contact with the outside world;
58 hence, there is always a risk of infection by various pathogens in the outside world.
59 Therefore, the respiratory system develops various immune mechanisms in mucosal
60 tissues, particularly, innate immunity (Ackermann et al., 2010), which is mostly
61 dependent on alveolar macrophages (Batista et al., 2012; Bertagnon et al., 2019). In
62 experimental models of humans and animals, alveolar macrophages exhibit plasticity and
63 maintain lung homeostasis by altering their function (Hussell and Bell, 2014). The
64 maintenance and alteration of these functions are regulated by the alveolar
65 microenvironment, particularly by fluid factors, including cytokines and pathogen-
66 associated molecular patterns (PAMPs).

67 When pathogens invade a host, pattern recognition receptors (PRRs) expressed
68 by alveolar macrophages are activated by recognizing bacterial and viral PAMPs and

69 produce type I interferons (IFNs) and proinflammatory cytokines, thus, changing the
70 immune dynamics from a steady state to an unbalanced state (Aggarwal et al., 2014).
71 Subsequently, the production of chemokines and the collection of neutrophils and
72 lymphocytes are enhanced. Lymphocytes produce IFN- γ (type II IFN), or IFN- β (type I
73 IFN) which polarizes alveolar macrophages to classically activated (M1)-like
74 inflammatory states which improve pathogen clearance (Herold et al., 2011), or to
75 alternatively activated (M2)-like phenotypes which resolve inflammation and repair the
76 alveolar environment (Hussell and Bell, 2014; Kumaran Satyanarayanan et al., 2019),
77 respectively. Thus, the function of alveolar macrophages is regulated by various humoral
78 factors and PAMPs, but all the above findings are from humans and experimental animals,
79 and there are few reports in bovine.

80 Epidemiological studies showed that the tuberculosis vaccine, BCG, protects
81 against childhood mortality caused by non-antigenic pathogens (Levine and Sackett,
82 1946). Subsequent numerous studies have shown its ability to induce a strong protective
83 effect against other infectious diseases, due to “non-specific effects (NSEs)” (Netea et al.,
84 2020) which is induced by the recognition of PAMPs in BCG by various immune cells
85 (Covian et al., 2019). Studies in mice have shown that intranasal BCG directly affects
86 alveolar macrophages and influences secondary viral infections in the respiratory mucosa

87 (Mukherjee et al., 2017). A report from Japan suggests that nasal cavity-administered
88 modified-live viral (MLV) vaccines also protect against infection by non-antigenic
89 pathogens in bovines (Aoki, 2019; Kano, 2018), but the immunological basis is unknown.

90 In the present study, we investigated the regulatory role of MLV vaccines in
91 bovine alveolar macrophages. As an NSEs effect of MLV vaccines, we hypothesized the
92 activation of non-specific innate immune mechanisms in alveolar macrophages. Common
93 nonspecific innate immune mechanisms of macrophages include production of
94 inflammatory cytokines (tumor necrosis factor alpha: TNF- α) induced by the nuclear
95 factor kappa B pathway, inducible NO synthase (iNOS), which synthesizes NO, type I
96 interferon (IFN- α , β) induced by the interferon regulatory factor pathway. In the above-
97 mentioned processes, PRRs such as Toll like receptors, RIG-I like receptors, and NOD
98 like receptors activate signal transduction circuits when PAMPs are recognized, and
99 increase mRNA (Akira et al., 2006). We stimulated alveolar macrophages *in vitro* with
100 lipopolysaccharide (LPS), a bacterial PAMP, polyinosinic-polycytidylic acid sodium salt
101 (Poly I:C), a synthetic RNA analog mimicking viral PAMPs, IFN- γ , and MLV vaccine,
102 respectively, and analyzed the changes in tumor necrosis factor alpha (TNF- α), inducible
103 nitric oxide synthase (iNOS), and IFN- β mRNA expression levels.

104

105 2. Materials and methods

106 2.1. Animals

107 This study was approved by the Animal Care and Use Committee of the Feed
108 Research Institute of the University of Miyazaki (No. 2017-016-1). All experimental
109 procedures were approved and carried out according to the guidelines of the committee.
110 We used six Japanese Black cattle (aged 30 – 42 months old), born between December 8,
111 2018, and March 7, 2019, and raised them according to standard guidelines at the
112 Sumiyoshi Livestock Science Station (Miyazaki, Japan) which had Global G.A.P.
113 certification (GGN: 4052852881722). **BALF samples** were collected from cattle that
114 were systemically healthy, which did not have a chronic or immediate history of
115 respiratory disease.

116

117 2.2. Bronchoalveolar lavage fluid (BALF)

118 While holding the cattle, a flexible electronic endoscope (VQ TYPE 5112 B,
119 Olympus, Tokyo, Japan) was inserted through the nasal passage to the carina, and its
120 distal end was then passed into a main stem bronchus. The flexible electronic endoscope
121 was then inserted into a subsegment of each lobe. Three 30 mL aliquots of sterile 0.9 %
122 normal saline solution were infused into the lobes and immediately aspirated. All

123 aspirations were pooled, and the volume of the BALF was measured and recorded.
124 Additionally, BALF was collected from the right cranial lobe, and a part of the BALF
125 was used for microbiological tests and was confirmed to be negative. No secondary
126 symptoms were observed after BALF collection.

127

128 2.3. Alveolar macrophage processing

129 After measuring their volumes, the **BALF samples** were filtered using sterilized
130 gauze and centrifuged ($400 \times g$ for 10 min at 4°C) to separate their cellular components.
131 The number of total nucleated cells was counted using a Countess Li FL automated cell
132 counter (Thermo Fisher Scientific, Waltham, MA, USA). **Sample was diluted with equal**
133 **volume of PBS and carefully layered 20 ml of diluted sample over the two 4ml**
134 **Lympholyte-H (Cederlane Lab., Ontario, Canada) in 15 ml tube. Centrifuge for 60**
135 **minutes at $800 \times g$ at room temperature. The interface layer was placed into a new 15ml**
136 **tube, washed three times in PBS. After additional wash, cells were resuspended and**
137 **cryopreserved in CELLBANKER 2 (Takara Bio Inc., Shiga, Japan) and kept frozen at -**
138 **80°C for later use.**

139

140 2.4. Stimulated culture

141 Alveolar macrophages (2×10^5 cells) were cultured in 1mL of Roswell Park
142 Memorial Institute 1640 medium (Fujifilm Wako Pure Chemical Corporation, Osaka,
143 Japan) containing 10 % FBS (Japan Bioserum Co. Ltd., Hiroshima, Japan) and 1 %
144 penicillin-streptomycin-amphotericin B suspension ($\times 100$ solution; Fujifilm Wako Pure
145 Chemical Corporation) in 12-well plates in 5 % CO₂ at 37 °C with stimulation. Cultures
146 were stimulated with 1 μ g/mL LPS, 25 μ g/mL Poly I:C (Sigma Aldrich, St. Louis, MO,
147 USA), 1 μ L/mL MLV vaccine-1, 10 μ L/mL MLV vaccine-10, 100 μ L/mL MLV vaccine-
148 100, 100 μ L/mL ultraviolet (UV)-irradiated MLV vaccine-100, or 5 ng/mL IFN- γ
149 (Thermo Fisher Scientific) for 24 h. The MLV vaccine (Inforce-3; Zoetis, Kalamazoo, MI,
150 USA) containing temperature-sensitive variants of bovine herpesvirus type 1 (BoHV-1),
151 bovine parainfluenza virus type 3 (BPIV-3), and bovine respiratory syncytial virus
152 (BRSV) were used for stimulation. Approximately 2.86×10^7 copies/mL of BoHV-1
153 DNA were used. UV irradiation using the UV cross-linker FS-1500 for 5 min kills the
154 virus particles which are then used in the MLV vaccine (Rajan et al., 2011).

155

156 2.5. Quantitative reverse transcription PCR (RT q-PCR)

157 Total RNA was isolated using RNAiso Plus Total RNA extraction reagent
158 (Takara Bio Inc.) and Direct-zol RNA MiniPrep kit (Zymo Research, Irvine, CA, USA)

159 according to the manufacturers' protocols. RNA concentration and purity were measured
160 using a nanophotometer (Wako, Kyoto, Japan). The total RNA was used as a template for
161 complementary DNA synthesis using the PrimeScript RT reagent kit (Takara) according
162 to the manufacturer's protocol. Real-time quantitative PCR reactions were performed
163 using TB Green Premix Ex Taq II (Takara). Cycling conditions were as follows: 95 °C
164 for 30 s; 40×: 95 °C for 5 s, 60 °C for 30 s; 95 °C for 15 s, 60 °C for 1 min, and 95 °C for
165 15 s. Quantitative evaluation of mRNA was performed using a StepOnePlus™ Real-Time
166 PCR System (Applied Biosystems, Foster City, CA, USA). Values were normalized to
167 those of β -actin. Changes in gene expression were calculated using the $\Delta\Delta C_t$ method. The
168 oligonucleotide primer sequences used are shown in Table 1. All experiments were
169 independently replicated in duplicates.

170

171 2.6. Data statistics

172 Statistical data for unstimulated and stimulated samples were obtained using the
173 Kruskal-Wallis and Dunn's multiple comparison tests using GraphPad Prism Software
174 (version 7.05; GraphPad Software Inc., San Diego, CA, USA).

175

176 3. Results and discussion

177 This study revealed that mRNA expression levels in bovine alveolar
178 macrophages were altered by stimulation with PAMPs, cytokines, and vaccines, and that
179 these changes were different depending on the type of stimulus. We analyzed TNF- α ,
180 iNOS, and IFN- β which cause changes in alveolar macrophage function due to changes
181 in mRNA expression in humans and experimental animals (Aggarwal et al., 2014).

182 TNF- α expression in bovine alveolar macrophages was significantly upregulated
183 by IFN- γ and MLV vaccines (Fig. 1a), and iNOS expression was significantly upregulated
184 by LPS, IFN- γ , and MLV vaccine stimulation (Fig. 1b). Inflammation, which activates
185 and induces immune cells to eliminate pathogens, is essential for the healing of infectious
186 pneumonia, and TNF- α and nitric oxide induced by iNOS are important for the initiation
187 of inflammation. However, **cytokine storms can cause excessive inflammation**, which can
188 lead to more severe symptoms (Fajgenbaum and June 2020). In acute respiratory
189 syndrome coronavirus 2 (SARS-COV-2) pneumonia, a feedback loop of infected
190 macrophages and IFN- γ produced by T cells leads to excessive alveolar inflammation
191 (Grant et al., 2021). Importantly, these modulations may increase anti-pathogen activity
192 and increase the risk of symptom exacerbation.

193 IFN- β is a type I IFN which provides antiviral immunity, and when produced by
194 alveolar macrophages, acts on autocrine cells and promotes the resolution of

195 inflammation in the respiratory tract (Connolly and Hussell, 2020). Additionally,
196 individuals with severe SARS-COV-2 pneumonia have impaired responses to IFN- β ,
197 which may be the reason for the difference in host immune responses (Hadjadj et al.,
198 2020). In the present study, only the MLV vaccine significantly increased the IFN- β
199 expression (Fig. 1c). We believe that elucidation of the mechanism by which IFN- β
200 expression is increased in alveolar macrophages will be an important key point in the
201 development of preventive and therapeutic measures against BRD, and we plan to
202 conduct further analyses.

203 The results of stimulation with the MLV vaccine were of particular interest in
204 this study. The expression levels of TNF- α , iNOS, and IFN- β , increased in a
205 concentration-dependent manner. The MLV vaccine did not contain any adjuvants.
206 BoHV-1 and BPIV-3 are temperature-sensitive strains that cannot infect or be amplified
207 under the present culture conditions. Moreover, BRSV is unstable and grows very poorly
208 in cell culture *in vitro* (Larsen, 2000), and amplification in macrophage-derived cells has
209 not been reported. Based on the above background and the result indicating that the same
210 effect was observed with a vaccine whose infectivity was eliminated by UV irradiation,
211 we believe that viral PAMPs contained in the MLV vaccine directly stimulated alveolar
212 macrophages. Importantly, a detailed examination of the stimulatory or cooperative

213 effects of PAMPs in the three viruses should be conducted. Furthermore, it has been
214 reported that the nasally administered MLV vaccine used in this study does not proliferate
215 in the deep respiratory tract when administered to cattle, but the virus particles themselves
216 do reach the site (Walz et al., 2017). Although it is unclear whether the phenomenon
217 observed *in vitro* is also observed *in vivo*, we hypothesized that virus particles contained
218 in the MLV vaccine administered into the nasal cavity reach the respiratory mucosa and
219 directly stimulate alveolar macrophages. If the interrelationship between alveolar
220 macrophages and PAMPs can be elucidated in detail, it is expected to induce more
221 effective and controlled NSEs.

222 The limitations of this study and future prospects are described below. Whether
223 the upregulation of mRNA expression of IFN- β , TNF- α , and iNOS in bovine alveolar
224 macrophages has the same effect as in humans and experimental animals requires further
225 analysis at the protein and infectivity testing levels. To elucidate the details of the
226 stimulatory response and NSEs induced by PAMPs, including the MLV vaccine, it is
227 important to analyze their relationship with PRRs. However, the RIG-I like receptor
228 family, which has been reported to be particularly important as a viral receptor in humans
229 and mice, has not been reported in cattle (Takeuchi and Akira, 2009), the expression
230 and function of PRRs in bovine alveolar macrophages should be elucidated first.

231 In summary, this study revealed that mRNA expression levels in bovine alveolar
232 macrophages were altered by stimulation with cytokines and PAMPs. Therefore, it is
233 likely that bovine alveolar macrophages have plasticity, which is regulated by cytokines
234 and PAMPs. In addition, nasal mucosal MLV vaccine stimulation also resulted in large
235 fluctuations in the mRNA expression levels. We believe that this suggests the potential
236 application of NSEs as a candidate for a new preventive strategy against bovine infectious
237 diseases. Further elucidation of the factors and methods that induce NSEs most potently
238 and analyze the plasticity and regulatory mechanisms of alveolar macrophages will
239 contribute to the understanding of the pathogenesis of BRD and the development of
240 preventive and therapeutic measures.

241

242 Declarations

243 Ethics approval

244 This study was approved by the Animal Care and Use Committee of the Feed
245 Research Institute of the University of Miyazaki which approved all experimental
246 procedures (No. 2017-016-1).

247

248 Conflict of Interest

249 The authors declare the following financial interests/personal relationships that
250 may be considered potential conflict of interests: SI received research funding from Zoetis
251 Japan Inc. None of the other authors have conflicting financial interests.

252

253 Funding

254 This work was supported by JSPS KAKENHI [grant number JP19K16002]
255 and CADIC for Joint Research Projects, University of Miyazaki (2019). The funding
256 body had no role in the design of the study, collection, analysis, and interpretation of data,
257 or in writing the manuscript.

258

259 Acknowledgements

260 The authors would like to thank Editage (www.editage.jp) for English language
261 editing.

262

263 References

264 Ackermann, M.R., Derscheid, R., Roth, J.A., 2010. Innate immunology of bovine
265 respiratory disease. *Vet Clin North Am Food Anim Pract* 26, 215-228.
266 Aggarwal, N.R., King, L.S., D'Alessio, F.R., 2014. Diverse macrophage populations

267 mediate acute lung inflammation and resolution. *Am J Physiol Lung Cell Mol*
268 *Physiol* 306, L709-725.

269 Akira, S., Uematsu, S., Takeuchi, O., 2006. Pathogen recognition and innate immunity.
270 *Cell* 124, 783-801.

271 Aoki, T., 2019. [Use of a nasal mucosal vaccine reduces disease incidence in calves on a
272 beef cattle feedlot.] *Nikuushi hiikunoujo ni okeru bikuunenmaku vaccine no*
273 *shiyou ga koushi no shippei rikanritsu wo teigen saseta jirei* (in Japanese). *MP*
274 *agro journal*. *MP agro journal* 36, 29-33.

275 Batista, C.F., Blagitz, M.G., Santos, B.P., Bertagnon, H.G., Parra, A.C., Vianna, R.S., de
276 Lucca, G.G., Lima, D.M., Santos, D.S., Della Libera, A.M., 2012. Maturation of
277 mononuclear phagocytes in the lungs of young calves--in vitro study. *J Dairy Sci*
278 95, 5909-5915.

279 Bertagnon, H.G., Batista, C.F., Santos, K.R., Gomes, R.C., Bellinazzi, J.B., Della Libera,
280 A., 2019. Alveolar macrophage functions during the transition phase to active
281 immunity in calves. *J Anim Sci* 97, 982.

282 Connolly, E., Hussell, T., 2020. The Impact of Type 1 Interferons on Alveolar
283 Macrophage Tolerance and Implications for Host Susceptibility to Secondary
284 Bacterial Pneumonia. *Front Immunol* 11, 495.

285 Covian, C., Fernandez-Fierro, A., Retamal-Diaz, A., Diaz, F.E., Vasquez, A.E., Lay, M.K.,
286 Riedel, C.A., Gonzalez, P.A., Bueno, S.M., Kalergis, A.M., 2019. BCG-Induced
287 Cross-Protection and Development of Trained Immunity: Implication for Vaccine
288 Design. *Front Immunol* 10, 2806.

289 Edwards, T.A., 2010. Control methods for bovine respiratory disease for feedlot cattle.
290 *Vet Clin North Am Food Anim Pract* 26, 273-284.

291 Fajgenbaum, D.C., June, C.H., 2020. Cytokine Storm. *N Engl J Med* 383, 2255-2273.

292 Grant, R.A., Morales-Nebreda, L., Markov, N.S., Swaminathan, S., Querrey, M., Guzman,
293 E.R., Abbott, D.A., Donnelly, H.K., Donayre, A., Goldberg, I.A., Klug, Z.M.,
294 Borkowski, N., Lu, Z., Kihshen, H., Politanska, Y., Sichizya, L., Kang, M.,
295 Shilatifard, A., Qi, C., Lomasney, J.W., Argento, A.C., Kruser, J.M., Malsin, E.S.,
296 Pickens, C.O., Smith, S.B., Walter, J.M., Pawlowski, A.E., Schneider, D.,
297 Nannapaneni, P., Abdala-Valencia, H., Bharat, A., Gottardi, C.J., Budinger,
298 G.R.S., Misharin, A.V., Singer, B.D., Wunderink, R.G., Investigators, N.S.S.,
299 2021. Circuits between infected macrophages and T cells in SARS-CoV-2
300 pneumonia. *Nature* 590, 635-641.

301 Griffin, D., Chengappa, M.M., Kuszak, J., McVey, D.S., 2010. Bacterial pathogens of the
302 bovine respiratory disease complex. *Vet Clin North Am Food Anim Pract* 26, 381-

303 394.

304 Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Pere, H., Charbit,
305 B., Bondet, V., Chenevier-Gobeaux, C., Breillat, P., Carlier, N., Gauzit, R.,
306 Morbieu, C., Pene, F., Marin, N., Roche, N., Szwebel, T.A., Merklings, S.H.,
307 Treluyer, J.M., Veyer, D., Mouthon, L., Blanc, C., Tharaux, P.L., Rozenberg, F.,
308 Fischer, A., Duffy, D., Rieux-Laucat, F., Kerneis, S., Terrier, B., 2020. Impaired
309 type I interferon activity and inflammatory responses in severe COVID-19
310 patients. *Science* 369, 718-724.

311 Herold, S., Mayer, K., Lohmeyer, J., 2011. Acute lung injury: how macrophages
312 orchestrate resolution of inflammation and tissue repair. *Front Immunol* 2, 65.

313 Hussell, T., Bell, T.J., 2014. Alveolar macrophages: plasticity in a tissue-specific context.
314 *Nat Rev Immunol* 14, 81-93.

315 Kano., Y., 2018. Measureas against bovine respiratory syncytial virus disease in calves
316 considered by clinical veterinarian. *The Journal of Farm Animal in Infectious*
317 *Disease* 7, 119-127.

318 Kumaran Satyanarayanan, S., El Kebir, D., Soboh, S., Butenko, S., Sekheri, M., Saadi, J.,
319 Peled, N., Assi, S., Othman, A., Schif-Zuck, S., Feuermann, Y., Barkan, D., Sher,
320 N., Filep, J.G., Ariel, A., 2019. IFN- β is a macrophage-derived effector cytokine

321 facilitating the resolution of bacterial inflammation. *Nat Commun* 10, 3471.

322 Larsen, L.E., 2000. Bovine respiratory syncytial virus (BRSV): a review. *Acta Vet Scand*
323 41, 1-24.

324 Levine, M.I., Sackett, M.F., 1946. Results of BCG immunization in New York City. *Am*
325 *Rev Tuberc* 53, 517-532.

326 Maunsell, F.P., Woolums, A.R., Francoz, D., Rosenbusch, R.F., Step, D.L., Wilson, D.J.,
327 Janzen, E.D., 2011. *Mycoplasma bovis* infections in cattle. *J Vet Intern Med* 25,
328 772-783.

329 Mukherjee, S., Subramaniam, R., Chen, H., Smith, A., Keshava, S., Shams, H., 2017.
330 Boosting efferocytosis in alveolar space using BCG vaccine to protect host against
331 influenza pneumonia. *PLoS One* 12, e0180143.

332 Netea, M.G., Giamarellos-Bourboulis, E.J., Dominguez-Andres, J., Curtis, N., van Crevel,
333 R., van de Veerdonk, F.L., Bonten, M., 2020. Trained Immunity: a Tool for
334 Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. *Cell* 181,
335 969-977.

336 Rajan, J.V., Rodriguez, D., Miao, E.A., Aderem, A., 2011. The NLRP3 inflammasome
337 detects encephalomyocarditis virus and vesicular stomatitis virus infection. *J Virol*
338 85, 4167-4172.

339 Takeuchi, O., Akira, S., 2009. Innate immunity to virus infection. *Immunol Rev* 227, 75-

340 86.

341 Walz, P.H., Newcomer, B.W., Riddell, K.P., Scruggs, D.W., Cortese, V.S., 2017. Virus

342 detection by PCR following vaccination of naive calves with intranasal or

343 injectable multivalent modified-live viral vaccines. *J Vet Diagn Invest* 29, 628-

344 635.

345

346 **Figure legend**

347 Fig. 1. Changes in bovine alveolar macrophages. Changes in (a) tumor necrosis factor

348 alpha (TNF- α), (b) inducible nitric oxide synthase (iNOS), and (c) interferon beta (IFN-

349 β) mRNA expression in alveolar macrophages (2×10^5) stimulated by lipopolysaccharide

350 (LPS; 1 $\mu\text{g}/\text{mL}$), polyinosinic-polycytidylic acid sodium salt (Poly I:C; 25 $\mu\text{g}/\text{mL}$),

351 interferon gamma (IFN- γ ; 5 ng/mL), modified-live viral (MLV) vaccine-1 (1 $\mu\text{L}/\text{mL}$),

352 MLV vaccine-10 (10 $\mu\text{L}/\text{mL}$), MLV vaccine-100 (100 $\mu\text{L}/\text{mL}$), UV-irradiated MLV

353 vaccine-100UV (100 $\mu\text{L}/\text{mL}$), or non-stimulated (control). Alveolar macrophages were

354 collected 24 h after stimulation. Analysis of relative gene expression data using real-time

355 quantitative PCR and the $\Delta\Delta\text{Ct}$ method was assessed. Each value was normalized to that

356 of β -actin mRNA and fold-changes in the gene of each stimulation were calculated by

357 referring to the value of the control. Dot plots of individual stimulations: control (circle),
358 LPS (square), Poly I:C (triangle), IFN- γ (inverted triangle), MLV-1 (rhombus), MLV-10
359 (white circle), MLV-100 (white square), MLV-100UV (white triangle), and mean are
360 shown (n=6). Data are representative of two independent experiments. Significant
361 differences between the control and stimulated cells are denoted as *p<0.05, **p<0.01,
362 ***p<0.001, or ****p<0.0001.